R. Julian

Phase II Trial of CDX-3379 and Cetuximab in Recurrent/Metastatic, HPV-Negative, Cetuximab-Resistant Head and Neck Cancer

J. Bauman, U. Duvvuri, T. Wise-Draper, 2022, Cancers.

Immunotherapy Approaches in HPV-Associated Head and Neck Cancer

J. Bauman, M. Savani, R. Julian, 2021, Cancers.

The impact of socioeconomic and geographic factors on access to transoral robotic/endoscopic surgery for early stage oropharyngeal malignancy.

J. Bauman, Steven J. Wang, J. Robbins, 2021, American journal of otolaryngology.

798 Safety, tolerability, and immunogenicity of mRNA-4157 in combination with pembrolizumab in subjects with unresectable solid tumors (KEYNOTE-603): an update

J. Bauman, H. Burris, J. Frederick, 2020 .

Outcomes of advanced pulmonary large cell neuroendocrine carcinoma stratified by RB1 loss, SLFN11 expression, and tumor mutational burden.

A. Drilon, C. Rudin, N. Rekhtman, 2018 .

2017–2018 Scientific Advances in Thoracic Oncology: Small Cell Lung Cancer

Shuhang Wang, J. Wolf, L. Gandhi, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Tell Me Your Story: A Pilot Narrative Medicine Curriculum During the Medicine Clerkship

Katherine C. Chretien, R. Kheirbek, Rebecca S Swenson, 2015, Journal of General Internal Medicine.

Randomized Phase II Trial of Ficlatuzumab With or Without Cetuximab in Pan-Refractory, Recurrent/Metastatic Head and Neck Cancer

J. Bauman, C. Caulin, B. Burtness, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

71P A phase II study of ADU-S100 in combination with pembrolizumab in adult patients with PD-L1+ recurrent or metastatic HNSCC: Preliminary safety, efficacy and PK/PD results

D. Nuyten, R. Ferris, R. Mehra, 2020 .

Abstract 3349: Optimizing radioimmunotherapy techniques for the alpha-emitter 225Actinium

E. Dadachova, E. Revskaya, Hyun A. Song, 2015 .